Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol

BMC Pregnancy and Childbirth

Volumn 12, Issue , 2012, Pages

  Alonso Coello, Pablo ^a   Ebrahim, Shanil ^b   Guyatt, Gordon H ^b   Tikkinen, Kari A O ^b,c   Eckman, Mark H ^d   Neumann, Ignacio ^b,e   McDonald, Sarah D ^b   Akl, Elie A ^b,f   Bates, Shannon M ^b,g  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b MCMASTER UNIVERSITY   (Canada)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f UNIVERSITY AT BUFFALO   (United States)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; FEMALE; HUMAN; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PATIENT DECISION MAKING; PATIENT PREFERENCE; PREGNANCY; THERMOMETER; THROMBOSIS PREVENTION; VASECTOMY; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CHOICE BEHAVIOR; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MARKOV CHAINS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RECURRENCE; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 84861547101     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-12-40     Document Type: Article

References (88)

1. McColl MD, Ellison J, Greer IA, Tait AC, Walker ID. Prevention of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol 2000, 108:272-274. 10.1046/j.1365-2141.2000.01877.x, 10691854.
2. Lewis G. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer - 2003-2005. Confidential Enquiry into Maternal and Child Health: The Sixth Report of the Confidential Enquiries into Maternal Death in the United Kingdom 2007, RCOG Press, London.
3. Chang J, Elam-Evans LD, Berg CJ, Herdon J, Flowers L, Seed KA, Syverson CJ. Pregnancy-related mortality surveillance- United States, 1991-1999. MMWR Surveill Summ 2003, 52:1-88.
4. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194:1311-1315. 10.1016/j.ajog.2005.11.008, 16647915.
5. Weindling AM. The confidential enquiry into maternal and child health (CEMACH). Arch Dis Child 2003, 88:1034-1037. 10.1136/adc.88.12.1034, 1719387, 14670760.
6. Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002, 100:1060-1062. 10.1182/blood-2002-01-0149, 12130523.
7. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J 1974, 1:215-217. 10.1136/bmj.1.5901.215, 1633083, 4818161.
8. Tengborn L, Bergqvist D, Matzsch T, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet gynecol 1989, 160:90-94.
9. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G, . Recurrence of Clot in This Pregnancy Study Group Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence Of Clot In This Pregnancy Study Group. N Engl J Med 2000, 343:1439-1444. 10.1056/NEJM200011163432002, 11078768, Recurrence of Clot in This Pregnancy Study Group.
10. de Swiet M, Floyd E, Letsky E. Low risk of recurrent thromboembolism in pregnancy. Br J Hosp Med 1987, 38:264.
11. Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynaecol 1983, 90:1124-1128. 10.1111/j.1471-0528.1983.tb06458.x, 6360198.
12. De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio Mannucci P, Leone G. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006, 135:386-391. 10.1111/j.1365-2141.2006.06317.x, 16984390.
13. Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thromboembolism. J Thromb Haemost 2005, 3:949-954. 10.1111/j.1538-7836.2005.01307.x, 15869590.
14. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003, 362:523-526. 10.1016/S0140-6736(03)14111-6, 12932383.
15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005, 293:2352-2361. 10.1001/jama.293.19.2352, 15900005.
16. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000, 160:769-774. 10.1001/archinte.160.6.769, 10737276.
17. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768. 10.1001/archinte.160.6.761, 10737275.
18. Iori A, Kearon C, Filippuci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch intern Med 2010, 170:1710-1716. 10.1001/archinternmed.2010.367, 20975016.
19. Kearon C. Risk factors for recurrent venous thromboembolism and their implications for treatment. Deep venous thrombosis 2004, 439-456. Hematology (Am Hem Soc Hematol Educ Program), Lopez JA, Kearon C, Lee AYY.
20. Kearon C, Ginsberg JS, Anderson DR, Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M, . for the SOFAST Investigators Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004, 2:743-749. 10.1046/j.1538-7836.2004.00698.x, 15099280, for the SOFAST Investigators.
21. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995, 74:606-611.
22. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP, . for the DOTAVK Study Comparison of 3 and 6 months of anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001, 103:2453-2460. 10.1161/01.CIR.103.20.2453, 11369685, for the DOTAVK Study.
23. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-1133. 10.1056/NEJM199210153271604, 1528208.
24. Research Committee of the British Thoracic Society Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992, 340:873-876. Research Committee of the British Thoracic Society.
25. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, . for the Duration of Anticoagulation Trial Study Group A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661-1665. 10.1056/NEJM199506223322501, 7760866, for the Duration of Anticoagulation Trial Study Group.
26. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, . for the Warfarin Optimal Duration Italian Trial Investigators Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med 2001, 345:165-169. 10.1056/NEJM200107193450302, 11463010, for the Warfarin Optimal Duration Italian Trial Investigators.
27. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P, . for the Warfarin Optimal Duration Italian Trial Investigators Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003, 130:19-25. for the Warfarin Optimal Duration Italian Trial Investigators.
28. Campbell A, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ. Anticoagulation for three months versus six months in patients with deep vein thrombosis or pulmonary embolism or both: randomised trial. BMJ 2007, 334:674-680. 10.1136/bmj.39098.583356.55, 1839169, 17289685.
29. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907. 10.1056/NEJM199903253401201, 10089183.
30. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:2453-2460. 10.1056/NEJMe030081, 12802032.
31. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997, 77:624-628.
32. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stümpflen A, Schneider B, Lechner K, Kyrle PA. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999, 81:14-17.
33. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006, 166:729-736. 10.1001/archinte.166.7.729, 16606808.
34. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1961A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999, 81:684-689.
35. Middeldorp S. Thrombophilic defects. Thrombophilia and new anticoagulant drugs 2004, 424-438. Hematology (Am Hem Soc Hematol Educ Program), Weitz JI, Middeldorp S, Geerts W, Heit JA.
36. Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001, 37:215-218. 10.1016/S0735-1097(00)01080-9, 11153741.
37. Palareti G, Legnani C, Cosmi B, Valdré L, Lunghi B, Bernardi F, Coccheri S. Predictive value of d-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous diopathic event and in carriers of congenital thrombophilia. Circulation 2003, 108:313-318. 10.1161/01.CIR.0000079162.69615.0F, 12847064.
38. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995, 92:2800-2802. 10.1161/01.CIR.92.10.2800, 7586244.
39. Schulman S, Lindmarker P, Holmstrom M, Lärfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006, 4:734-742. 10.1111/j.1538-7836.2006.01795.x, 16634738.
40. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M, Girolami A. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep vein thrombosis. Blood 2000, 96:3329-3333.
41. Chan W, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med 2000, 160:191-196. 10.1001/archinte.160.2.191, 10647757.
42. Ginsberg J, Hirsh J, Turner CD, Levine MN, Burrows R. Risk to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989, 61:197-203.
43. Hall J, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980, 68:122-140. 10.1016/0002-9343(80)90181-3, 6985765.
44. Hassouna A, Allam H. Anticoagulation of pregnant women with mechanical heart valve prosthesis: a systematic review of the literature (2000-2009). J Coagul Disorders 2010, 2:81-88.
45. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular-weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy, study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34:557-560. 10.1016/0049-3848(84)90260-3, 6740572.
46. Bates S, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8the Edition). The Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2008, 133:844S-886S. 10.1378/chest.08-0761, 18574280.
47. Greer I, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106:401-407. 10.1182/blood-2005-02-0626, 15811953.
48. Lepercq J, Conard J, Borel Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001, 108:1134-1140.
49. Rodie V, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low-molecular-weight heparin for treatment of venous thromboembolism in pregnancy: a case series. BJOG 2002, 109:1020-1024. 10.1111/j.1471-0528.2002.01525.x, 12269676.
50. Rowan J, McClintock C, Taylor RS, North RA. Prophylactic and therapeutic enoxaparin: indications, outcomes and monitoring. Aust NZ J Obstet Gynaecol 2003, 43:123-128.
51. Sanson B, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyák K, Theunissen IM, Hunt BJ, Büller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999, 81:668-672.
52. Smith M, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004, 190:495-501. 10.1016/S0002-9378(03)00953-0, 14981396.
53. Sorensen H, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Møller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scan 2000, 79:655-659.
54. Ulander V, Stenqvist P, Kaaja R. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. Thromb Res 2002, 106:13-17. 10.1016/S0049-3848(02)00074-9, 12165283.
55. Badawy A, Khiary M, Sherif LS, Hassan M, Ragab A, Abdelall I. Low molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 2008, 28:280-284. 10.1080/01443610802042688, 18569468.
56. Brenner B, Hoffman R, Carp H, Dulitsky M, . Younis J for the LIVE-ENOX Investigators Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005, 3:227-229. 10.1111/j.1538-7836.2004.01090.x, 15670024, Younis J for the LIVE-ENOX Investigators.
57. Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, . Greer IA on behalf of the Scottish Pregnancy Intervention Study (SPIN) collaborators SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010, 115:4162-4167. 10.1182/blood-2010-01-267252, 20237316, Greer IA on behalf of the Scottish Pregnancy Intervention Study (SPIN) collaborators.
58. Dargaud Y, Rugeri L, Ninet J, Negrier C, Treciak MC. Management of pregnant women with increaed risk of venous thrombosis. Int J Gynecol Obstet 2004, 90:203-207.
59. Darguad Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C, Bestion A, Desmurs-Clavel H, Ninet J, Gaucherand P, Rudigoz RC, Berland M, Champion F, Trzeciak MC. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol 2009, 145:825-835. 10.1111/j.1365-2141.2009.07698.x, 19388925.
60. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006, 86:362-366. 10.1016/j.fertnstert.2005.12.068, 16769056.
61. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey A-A A, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008, 278:33-38. 10.1007/s00404-007-0527-x, 18071727.
62. Gris J-C, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland M-L, Dauzat M, Mares P. Low molecular weight heparin versus low dose aspirin in women with one fetal loss and a constitutional thrombophic disorder. Blood 2004, 103:3695-3699. 10.1182/blood-2003-12-4250, 14739212.
63. Gris J-C, Chauleur C, Faillie J-L, Baer G, Mares P, Fabbro-Peray P, Quere I, Lefrant J-Y, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruption placentae. Thromb Haemost 2010, 104:771-779. 10.1160/TH10-03-0167, 20694277.
64. Kaandorp S, Goddijn M, van der Post JAM, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DNM, Buller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010, 362:1586-1596. 10.1056/NEJMoa1000641, 20335572.
65. Le Templier G, Rodger MA. Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 2008, 14:403-407. 10.1097/MCP.0b013e3283061191, 18664969.
66. Noble L, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low molecular weight heparin versus unfractionated heparin. Fertil Steril 2005, 83:684-690. 10.1016/j.fertnstert.2004.11.002, 15749498.
67. Regy E, Garneau P, David M, Gautheir R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009, 7:58-64. 10.1111/j.1538-7836.2008.03230.x, 19036070.
68. Warkentin T, Greinacher A, Koster A, Lincoff M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl):340S-380S. 10.1378/chest.08-0677, 18574270.
69. Tooher R, Gates S, Dowswell T, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD001689.
70. Gates S, Brocklehurst P, Ayers S, Bowler U, , et al. for the Thromboprophylaxis in Pregnancy Advisory Group Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol 2004, 191:1296-1303. 10.1016/j.ajog.2004.03.039, 15507957, for the Thromboprophylaxis in Pregnancy Advisory Group.
71. Geerts W, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (Eighth Edition). The Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2008, 133:381S-453S. 10.1378/chest.08-0656, 18574271.
72. Man-Son-Hing M, Gage BF, Montgomery AA, Howitt A, Thomson R, Devereaux PJ, Protheroe J, Fahey T, Armstrong D, Laupacis A. Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. Medical Decision Making 2005, 25:548-559. 10.1177/0272989X05280558, 16160210.
73. Llewellyn-Thomas H, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996, 16:262-272. 10.1177/0272989X9601600311, 8818125.
74. Llewellyn-Thomas H. Investigating patients' preferences for different treatment options. Can J Nurs Res 1997, 29:45-64.
75. Green C, Brazier J, Deverill M. Valuing health-related quality of life: a review of health state valuation techniques. Pharmacoeconomics 2000, 17:151-165. 10.2165/00019053-200017020-00004, 10947338.
76. Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ 1986, 5:1-30. 10.1016/0167-6296(86)90020-2, 10311607.
77. von Neuman J, Morgenstern O. Theory of Games and Economic Behaviour (3rd ed) 1953, Princeton University Press, Princeton, MJ, 3.
78. Puhan M, Guyatt G, Montori V, Devereaux PJ, Bhandari M, Griffith L, Goldstein R, Schünemann HJ. The standard gamble demonstrated lower reliability than the feeling thermometer. J Clin Epidemiol 2005, 58:458-465. 10.1016/j.jclinepi.2004.07.010, 15845332.
79. Schünemann H, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker states in chronic respiratory disease. Medical Decision Making 2003, 23:140-149. 10.1177/0272989X03251243, 12693876.
80. Schünemann H, Armstrong D, Fallone C, Barkun A, Degli'Innocenti A, Heels-Ansdell D, Wiklund I, Tanser L, Chiba N, Austin P, Van Zanten S, El-Dika S, Guyatt GH. A randomized multi-center trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care 2004, 42:32-42.
81. Schünemann H, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Bayoumi A, Austin P, Guyatt GH. Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease. Qual Life Res 2006, 14:1-14.
82. Schünemann H, Norman G, Puhan M, Griffith L, Wiklund I, Heels-Andell D, Montori VM, Goldstein R, Mador JM, Guyatt GH. Application of generalizability theory confirmed lower reliability of the standard gamble than the feeling thermometer. J Clin Epidemiol 2007, 60:1256-1262. 10.1016/j.jclinepi.2007.03.010, 17998080.
83. Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux PJ, Charles C, Roura M, Díaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Services Res 2008, 8:221-234.
84. Devereaux P, Anderson DR, Garner MJ. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001, 232:1211-1218.
85. Locadia M, Bossuyt PMM, Stalmeirer PFM, Sprangers MAG, van Dongen CJJ, Middeldorp S, Bank I, van der Meer J, Hamulyák K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patient' health valuations and treatment preferences. Thromb Haemost 2004, 92:1336-1341.
86. MacLean S. Evidence Based Medicine and Patient Choice: Recent Progress and Persisting Challenges 2010, McMaster University, Hamilton, ON.
87. Johnston J, Brill-Edwards P, Ginsberg JS, Pauker SG, Eckman MH. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. Am J Med 2005, 118:503-514. 10.1016/j.amjmed.2004.12.009, 15866253.
88. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974, 185:1124-1130. 10.1126/science.185.4157.1124, 17835457.